Next-Generation Oncolytic Virotherapies

Creating impactful drugs for patients with the highest medical need.

Virogin has developed an oncolytic HSV-1 platform capable of triggering long-lasting anti-tumor activity that leads to systemic cancer immunity.

Oncolytic virotherapy is among the most promising agents to induce immunogenicity and overcome immune-suppressive barriers in so-called “cold tumors” or relapsed/refractory patient populations.


Join our journey and be part of our team! Bring your passion and determination to make a difference in solving one of the world’s biggest challenges—a future without cancer.